Serum concentration of asprosin in new-onset type 2 diabetes

Naiemian, Shakiba; Naeemipour, Mohsen; Zarei, Mehdi; Najafi, Moslem Lari; Gohari, Ali; Behroozikhah, Mohammad Reza; Heydari, Hafez; Miri, Mohammad Bagher

doi:10.21203/rs.3.rs-15208/v3

Cited by 7 publications

(9 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Romere et al first demonstrated elevated plasma asprosin levels in humans and mice with IR, increased levels of glucose and 2h-insulin in fast mice undergoing continuous or pulsatile overexpression of asprosin, and a significant decrease in glucose and insulin levels, secondary to reduced hepatic glucose release, after immunologic or genetic asprosin action inhibition (4). Several studies have shown higher serum asprosin levels in subjects with IR and/or T2DM and a correlation between these pathological conditions and asprosin serum levels (8)(9)(10)(12)(13)(14). Wang et al documented higher plasma asprosin levels in IGR (including IFG and IGT subjects) and newly diagnosed T2DM patients compared to subjects with normal glucose regulation (NGR), showing a significant positive correlation between asprosin and HOMA-IR and a negative correlation between asprosin and HOMA-B (10).…”

Section: Discussionmentioning

confidence: 99%

Meal-Related Asprosin Serum Levels Are Affected by Insulin Resistance and Impaired Fasting Glucose in Children With Obesity

et al. 2022

View full text Add to dashboard Cite

Asprosin physiologically increases in fasting conditions and decreases with refeeding and has been implicated in glucose homeostasis. An alteration of meal-related circadian oscillation of asprosin has been suggested in adults affected by type 2 diabetes mellitus.Aims of this study were to test the hypothesis of an alteration in the meal-related variation of asprosin levels in non-diabetic children and adolescents with obesity and to assess which metabolic variables condition this variation in non-diabetic children and adolescents with obesity. This is a cross-sectional study which included 79 children and adolescents with obesity. Children underwent clinical and biochemical assessments, including oral glucose tolerance test (OGTT), and liver ultrasound evaluation. Asprosin serum levels were measured by an enzyme-linked immunosorbent assay at a fasting state and at the 120-minute OGTT timepoint (2h-postprandial asprosin). Fasting and 2h-postprandial asprosin serum levels did not significantly differ in the entire study population (374.28 ± 77.23 vs 375.27 ± 81.26;p=0.837). 55.7% of patients had a significant increase in 2h-postprandial asprosin compared with fasting levels. The asprosin level increase condition was significantly associated with HOMA-IR (OR,1.41; 95%CI,1.005-1.977; p=0.047), fasting glycaemia (OR,1.073; 95%CI,1.009-1.141;p=0.024) and HOMA-B (OR,0.99; 95%CI,0.984-0.999; p=0.035). Moreover, the IFG condition was associated with the increase in asprosin levels (OR, 3.040; 95%CI, 1.095-8.436; p=0.033), even after adjustment for HOMA-IR, BMI SDS, sex and pubertal stage. Insulin resistance and IFG influence meal-related changes of asprosin serum levels in our study population of obese, non-diabetic, children. Alteration of asprosin circadian secretion might be an early biomarker of impaired glucose regulation in obese children with insulin resistance.

show abstract

Section: Discussionmentioning

confidence: 99%

Meal-Related Asprosin Serum Levels Are Affected by Insulin Resistance and Impaired Fasting Glucose in Children With Obesity

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Asprosin deficiency may lead to loss of appetite and extreme leanness. [22] Diminished asprosin activity or asprosin depletion could be an innovative therapeutic modality for the treatment of T2DM and obesity, thus a potential target for diabetes treatment. [23]…”

Section: Discussionmentioning

confidence: 99%

Effects of GLP-1 receptor agonists on asprosin levels in normal weight or overweight/obesity patients with type 2 diabetes mellitus

Dai

Zhu

2022

Medicine

View full text Add to dashboard Cite

Asprosin is a newly identified adipokine with glucose-raising and appetite-enhancing effects which acts differently from the known hepatic glucose utilization pathway. This study investigated changes in serum asprosin levels in normal weight or overweight/ obese liraglutide-treated patients with type 2 diabetes (T2DM). This study is a non-randomized, prospective observational study. The metabolic parameters and asprosin levels were compared between 90 people with T2DM and 66 people who had normal glucose tolerance (NGT). During the treatment phase, only T2DM patients were given liraglutide at doses of 0.6 mg/d for the first 2 weeks, 1.2 mg/d for the subsequent 4 weeks, and 1.8 mg/d for the following 16 weeks. T2DM patients were separated into a normal weight group and an overweight/obesity group to compare changes in asprosin and parameters pre-and posttreatment. The T2DM group had significantly higher fasting asprosin and 2h-postprandial asprosin levels than the NGT group (all P < .001). Fasting asprosin and postprandial asprosin positively correlated with BMI, 2hPG, HbA1c, TG, and HOMA-IR, and negatively correlated with HDL-C in both the T2DM and NGT groups. Asprosin levels decreased after liraglutide treatment in both normal and overweight/obesity T2DM groups (all P < .001), with significantly reduced body weight and BMI in overweight/obese T2DM patients (all P < .001). Fasting and postprandial serum asprosin concentrations are higher in T2DM patients compared to normal glucose controls. Fasting and postprandial asprosin positively correlated with BMI, 2hPG, HbA1c, TG, and HOMA-IR and negatively correlated with HDL-C in all participants. Liraglutide lowers asprosin levels in T2DM patients and can reduce weight and BMI in overweight or obese type 2 diabetics. Abbreviations: 2hPG = 2h postprandial glucose, ALT = alanine aminotransferase, AST = aspartate aminotransferase, BMI = body mass index, BUN = blood urea nitrogen, Cr = creatinine, DBP = diastolic blood pressure, eGFR = estimated glomerular filtration rate, FBG = fasting glucose, HbA1c = glycated hemoglobin, HDL-C = HDL cholesterol, HOMA-IR = Homeostatic Model Assessment of Insulin Resistance, LDL-C = LDL cholesterol, NGT = normal glucose tolerance, SBP = systolic blood pressure, T2DM = type 2 diabetes mellitus, TC = total cholesterol, TG = triglycerides, WC = waist circumference.

show abstract

“…Moreover, higher circulating asprosin levels have also been noted in patients with newly diagnosed T2DM compared to healthy controls, with significant positive correlations to BMI, the homeostatic model assessment of insulin resistance (HOMA-IR) and both fasting blood glucose and triglyceride levels [44]. In addition, plasma asprosin concentrations appear to be even higher in patients with impaired glucose regulation (IGT) compared to patients with newly diagnosed T2DM [45].…”

Section: Asprosin In T2dmmentioning

confidence: 99%

Asprosin, a novel pleiotropic adipokine implicated in fasting and obesity-related cardio-metabolic disease: Comprehensive review of preclinical and clinical evidence

Shabir

Brown

Afzal

et al. 2021

Cytokine & Growth Factor Reviews

View full text Add to dashboard Cite

Serum concentration of asprosin in new-onset type 2 diabetes

Cited by 7 publications

References 19 publications

Meal-Related Asprosin Serum Levels Are Affected by Insulin Resistance and Impaired Fasting Glucose in Children With Obesity

Meal-Related Asprosin Serum Levels Are Affected by Insulin Resistance and Impaired Fasting Glucose in Children With Obesity

Effects of GLP-1 receptor agonists on asprosin levels in normal weight or overweight/obesity patients with type 2 diabetes mellitus

Asprosin, a novel pleiotropic adipokine implicated in fasting and obesity-related cardio-metabolic disease: Comprehensive review of preclinical and clinical evidence

Contact Info

Product

Resources

About